Entrada Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $203.51M
- P/E (TTM)
- –
- Dividend yield
- –
About Entrada Therapeutics
Pharmaceutical Preparations, SIC 2834
Entrada Therapeutics is a clinical-stage biopharmaceutical company focused on developing a class of genetic medicines that target disease-causing mechanisms inside cells. Utilizing its proprietary Endosomal Escape Vehicle platform, the company creates intracellular therapeutics by conjugating small cyclic peptides with oligonucleotides or proteins. Its core development pipeline focuses on rare neuromuscular conditions, particularly Duchenne muscular dystrophy, through exon-skipping candidates such as ENTR-601-44, ENTR-601-45, ENTR-601-50, and ENTR-601-51. In addition, the company collaborates with Vertex Pharmaceuticals to advance VX-670 for myotonic dystrophy type 1 and pursues preclinical programs for inherited ocular diseases, including ENTR-801 for Usher syndrome type 2A.
The company conducts clinical trials across multiple regions, with active development activities and regulatory engagements in the United States, the United Kingdom, and the European Union. Its pipeline targets rare genetic disease populations, addressing thousands of eligible patients amenable to exon-skipping therapies in both the United States and Europe. The provided text does not state the location of the company's headquarters.
Summary of the business section of Entrada Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Entrada Therapeutics, Inc.
- Headquarters
- Boston, MA
- Address
- One Design Center Place, Suite 17-500 02210
- Phone
- (857) 305-1825
- Employees
- 152, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- TRDA
- Exchange
- Nasdaq
- IPO date
- Nov 1, 2021
- Shares outstanding
- 39M, Jul 31, 2026
- Public float
- $191.20M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1689375
- CUSIP
- 29384C108
- ISIN
- US29384C1080
- EIN
- 81-3983399
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Dipal Doshi | CEO, Director | 517,290 |
| Kory James Wentworth | Chief Financial Officer | 117,277 |
| Natarajan Sethuraman | President, Research & Develop. | 214,238 |
| Nathan J. Dowden | President & COO | 196,060 |
| Kush Parmar | Director | 3,784,650 |
| Maha Radhakrishnan | Director | – |
| Peter S. Kim | Director | 117,412 |
| Mary Thistle | Director | – |
| Bernhardt G. Zeiher | Director | 5,000 |
| Gina Chapman | Director | – |
Employees
Headcount reported in annual reports
“As of February 19, 2026, we had 152 full-time employees, including a total of 64 employees with doctoral degrees or above.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Nov 1, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 26, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |
| Nov 10, 2016 | Name change | Name changed from CycloPorters, Inc. to Entrada Therapeutics, Inc. |